Market Place
Sourcing Support
Rhovac board member resigns due to health reasons
18 Oct 2022 //
PRNEWSWIRE
RhoVac’s Phase IIb prostate cancer trial fails to meet primary endpoint
30 May 2022 //
CLINICALTRIALSARENA
RhoVac AB announces Database Lock in clinical phase IIb trial of onilcamotide
10 May 2022 //
PRNEWSWIRE
Interim safety review of RhoVac`s clinical phase IIb study in prostate cancer
09 Dec 2021 //
PRNEWSWIRE
RhoVac presents 3-year follow-up results of the phI/II study in prostate cancer
05 Oct 2021 //
PRNEWSWIRE
Clean interim safety review of RhoVac`s clinical phase IIb study
09 Jul 2021 //
PRNEWSWIRE
Mount Sinai Hospital in New York joins RhoVac`s Phase IIb Study
21 Apr 2021 //
PRNEWSWIRE
Global Covid-19 Vaccination Roll-out causes delay to RhoVac`s Phase IIb study
08 Mar 2021 //
PRNEWSWIRE
First patient in treatment in RhoVac`s clinical phase IIb study in UK
07 Jan 2021 //
PRNEWSWIRE
Positive Results from RhoVac`s Clinical Phase I/II Study published
13 Nov 2020 //
PRNEWSWIRE
First patient in treatment in RhoVac`s clinical phase IIb study in Sweden
17 Sep 2020 //
PRNEWSWIRE
RhoVac begins patient enrollment in BRaVac phase IIb study in prostate cancer
10 Aug 2020 //
PHARMABIZ
First patient in treatment in RhoVac`s clinical phase IIb study in the USA
10 Aug 2020 //
PRNEWSWIRE
RhoVac receives approval in Sweden to start clinical phase IIb trial
22 Jun 2020 //
CISION
First Patient in Treatment in RhoVac`s Clinical Phase IIb Study in Germany
23 Apr 2020 //
PR NEWSWIR
Covid-19 Related Delays in the Ongoing Phase IIb-study are Expected
02 Apr 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.